{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:03:17Z","timestamp":1759341797710},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.lpm.2011.10.002","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T05:29:44Z","timestamp":1322803784000},"page":"1163-1173","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["L\u2019ophtalmopathie thyro\u00efdienne \u00e0 l\u2019heure de l\u2019European Group On Graves Orbitopathy (EUGOGO)"],"prefix":"10.1016","volume":"40","author":[{"given":"Jean-Louis","family":"Sadoul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2011.10.002_bib0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Graves\u2019 ophthalmopathy","volume":"360","author":"Bartalena","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.10.002_bib0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/thy.2010.1634","article-title":"Risk factors for development or deterioration of graves\u2019 ophthalmopathy","volume":"20","author":"Stan","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.lpm.2011.10.002_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/eje.1.02201","article-title":"A questionnaire survey on the management of Graves\u2019 orbitopathy in Europe","volume":"155","author":"Perros","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2265.2007.02854.x","article-title":"Susceptibility genes in Graves\u2019 ophthalmopathy: searching for a needle in a haystack?","volume":"67","author":"Bednarczuk","year":"2007","journal-title":"Clin Endcocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2011.10.002_bib0030","first-page":"1","article-title":"Cigarette smoking and thyroid eye disease: a systematic review","volume":"20","author":"Thornton","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.lpm.2011.10.002_bib0035","series-title":"Graves\u2019 orbitopathy: a multidisciplinary approach","article-title":"Clinical manifestations","author":"Dickinson","year":"2007"},{"key":"10.1016\/j.lpm.2011.10.002_bib0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.10.002_bib0045","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ophtha.2010.04.004","article-title":"Do subtypes of Graves\u2019 orbitopathy exist?","volume":"118","author":"Regensburg","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.lpm.2011.10.002_bib0050","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0029-1220935","article-title":"Current insights into the pathogenesis of Graves\u2019 orbitopathy","volume":"41","author":"Eckstein","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.lpm.2011.10.002_bib0055","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MED.0b013e32830eb8ab","article-title":"Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy","volume":"15","author":"Gianoukakis","year":"2008","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.lpm.2011.10.002_bib0060","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0065","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimu- lating hormone and insulin-like growth factor 1\u00a0receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3109\/01676831003668443","article-title":"The orbital fibroblast: a Key player and target for therapy in graves\u2019 ophthalmopathy","volume":"29","author":"van Steensel","year":"2010","journal-title":"Orbit"},{"key":"10.1016\/j.lpm.2011.10.002_bib0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0080","first-page":"177","article-title":"Development and course of exophtalmos and ophtalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"key":"10.1016\/j.lpm.2011.10.002_bib0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","article-title":"Natural history of thyroid-associated ophtalmopathy","volume":"42","author":"Perros","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2011.10.002_bib0090","series-title":"Graves\u2019 orbitopathy: a multidisciplinary approach","article-title":"Pathogenesis","author":"Orgiazzi","year":"2007"},{"key":"10.1016\/j.lpm.2011.10.002_bib0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1043-2760(02)00622-7","article-title":"Graves\u2019 ophtalmopathy: a rational approach to treatment","volume":"13","author":"Wiersinga","year":"2002","journal-title":"Trends Endocrinol Metab"},{"issue":"Suppl. 2","key":"10.1016\/j.lpm.2011.10.002_bib0100","first-page":"185","article-title":"Amelioration of eye changes of Graves\u2019 ophthalmopathy by achieving euthyroidism","volume":"121","author":"Prummel","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.lpm.2011.10.002_bib0105","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism","volume":"321","author":"Bartalena","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.10.002_bib0110","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves\u2019 disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","author":"Acharya","year":"2008","journal-title":"Clin Endcocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2011.10.002_bib0115","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Tr\u00e4isk","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0120","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2009-0506","article-title":"Graves\u2019 orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis","volume":"94","author":"Vannucchi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/thy.2010.1640","article-title":"The tale of radioiodine and Graves\u2019 orbitopathy","volume":"20","author":"Ponto","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.lpm.2011.10.002_bib0130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease-specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","article-title":"Psychosocial morbidity of Graves\u2019 orbitopathy","volume":"63","author":"Kahaly","year":"2005","journal-title":"Clin Endcocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2011.10.002_bib0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00234-009-0590-z","article-title":"Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves\u2019 orbitopathy: a pilot study at 1.5T","volume":"52","author":"Kirsch","year":"2010","journal-title":"Neuroradiology"},{"key":"10.1016\/j.lpm.2011.10.002_bib0145","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1507\/endocrj.K10E-156","article-title":"Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves\u2019 ophthalmopathy","volume":"57","author":"Tachibana","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.lpm.2011.10.002_bib0150","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for Graves\u2019 orbitopathy. Efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/jc.85.1.102","article-title":"Low- versus high-dose radiotherapy for Graves\u2019 ophthalmopathy: a randomized, single blind trial","volume":"85","author":"Kahaly","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0165","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study","volume":"355","author":"Mourits","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.10.002_bib0170","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 orbitopathy","volume":"108","author":"Gorman","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.lpm.2011.10.002_bib0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","article-title":"A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy","volume":"89","author":"Prummel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2006.094607","article-title":"Clinical features of dysthyroid optic neuropathy: a European Group on Graves\u2019 Orbitopathy (EUGOGO) survey","volume":"91","author":"McKeag","year":"2007","journal-title":"Br J Ophtalmol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment in Graves\u2019 ophthalmopathy? A randomized controlled trial","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2011.10.002_bib0190","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/bjo.2008.149302","article-title":"Outcome of orbital decompression for disfiguring proptosis in patients with Graves\u2019 orbitopathy using various surgical procedures","volume":"93","author":"Mourits","year":"2009","journal-title":"Br J Ophtalmol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1210\/jc.2002-020987","article-title":"Peroxysome proliferator-activated receptor-g in thyroid eye disease: contraindication for thiazolidinedione use?","volume":"88","author":"Starkey","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0200","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1515\/JPEM.2006.19.10.1193","article-title":"Thyroid-associated ophthalmopathy in juvenile Graves\u2019 disease clinical, endocrine and therapeutic aspects","volume":"19","author":"Krassas","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.lpm.2011.10.002_bib0205","first-page":"218","article-title":"Prevention of thyroid-associated ophthalmopathy in children and adults: current views and management of preventable risk factors","volume":"4","author":"Krassas","year":"2007","journal-title":"Pediatr Endocr Rev"},{"key":"10.1016\/j.lpm.2011.10.002_bib0210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20244","article-title":"Plasma filtration in the treatment of Graves\u2019 ophthalmopathy: a randomized study","volume":"25","author":"Cap","year":"2010","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.lpm.2011.10.002_bib0215","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.lpm.2011.10.002_bib0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20\u00a0monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2011.10.002_bib0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.lpm.2011.10.002_bib0230","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"European Group on Graves\u2019 Orbitopathy. Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"New Engl J Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211004957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211004957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T06:30:37Z","timestamp":1543386637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498211004957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0755498211004957"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2011.10.002","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}